Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liraglutide’s Future Uncertain: Panel Voices Concern Over Cancer And CV Risk

Executive Summary

Approval of Novo Nordisk's Victoza (liraglutide) for type 2 diabetes hinges on FDA's comfort with a safety database lacking on two fronts, an agency panel said April 2

You may also be interested in...



Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel

There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials

Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel

There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials

Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory

Approving Novo Nordisk's Victoza (liraglutide) for type 2 diabetes would require FDA to surmount a substantial hurdle in the thyroid cancer signal seen with the GLP-1 analog

Related Content

Topics

UsernamePublicRestriction

Register

PS050914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel